Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAP Block for Postoperative Pain After Cesarean Section
NCT07478692Completed
- Sponsor
- Qingyuan Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Qingyuan Pharmaceutical. Primary endpoints: Visual Analog Scale pain score at 48 hours, Time to first rescue analgesia requirement at 48 hours and 1 more. Started Jun 2025; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07478692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478692.